Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438   2/10/2026
4,458 CHF (-2,28%)
(-2,28%)   2/10/2026

11 augustus 2026 · Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule – Schedule V · Persbericht

30 juli 2026 · QUVIVIQ sales increased 62% year-on-year as Idorsia advances key drivers of future growth · Persbericht

27 juli 2026 · Idorsia advances global rollout of QUVIVIQ with Jamjoom Pharma partnership in Saudi Arabia and the Levant · Persbericht

23 juli 2026 · Invitation to Idorsia's HY 2026 Financial Reporting webcast and conference call · Persbericht

1 juli 2026 · Idorsia appoints Roland Wandeler as Chief Executive Officer · Persbericht

26 juni 2026 · Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility · Persbericht

9 juni 2026 · Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon · Persbericht

1 juni 2026 · Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology · Persbericht

1 juni 2026 · New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension · Persbericht

6 mei 2026 · Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2026 · Persbericht

28 april 2026 · Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year · Persbericht

10 april 2026 · Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders · Persbericht

9 april 2026 · Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development · Persbericht

30 maart 2026 · Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder · Persbericht

24 maart 2026 · Idorsia announces the nomination of three candidates for election to the Board of Directors · Persbericht

16 maart 2026 · Idorsia announces management change · Persbericht

10 maart 2026 · Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink · Persbericht

26 februari 2026 · Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026 · Persbericht

12 februari 2026 · Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call · Persbericht

6 februari 2026 · Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease · Persbericht

Mijn selecties